Publication: Expression of estrogen receptor,
progesterone receptor, and Her-2/ neu in
primary and extra-corporeal endometrial cancer
Authors
Tangjitgamol, Siriwan ; Tanvanich, Sujitra ; Srijaipracharoen, Sunamchok ; Manusirivithaya, Sumonmal
item.page.secondaryauthor
item.page.director
Publisher
F. Hernández y Juan F. Madrid. Universidad de Murcia: Departamento de Biología Celular e Histología
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Objective: To compare immunohistochemical
(IHC) expression of estrogen receptor (ER),
progesterone receptor (PR), and Her-2/neu in the
primary tumors of endometrial cancer (EMC) and their
extra-corporeal lesions.
Methods: Paraffin-embedded tissues of the primary
and extra-corporeal tumors of EMC were retrieved for
IHC study. Expression of ER, PR, and Her-2/ neu in the
primary tumors and extra-corporeal lesions were
compared.
Results: From 72 EMC patients with 87 extracorporeal
lesions, positive PR expression was
significantly lower in the extra-corporeal lesions than
that in the primary sites: 42.5% vs. 63.9%, respectively
(p=0.007). No statistically significant differences of ER
and Her-2/ neu expressions in the extra-corporeal and
the primary sites were found: 42.5% and 55.6% for ER
(p=0.102) and 20.7% vs. 13.9% for Her-2/ neu
(p=0.262), respectively. The expression of extracorporeal
lesions were concordant to the primary tumor
in 65.5% of ER (k=0.319), 71.2% of PR (k=0.445), and
83.9% of Her-2/ neu (k=0.413). From 15 cases wherein
IHC from two extra-corporeal sites were studied, 73%
had concordant ER expression between the two extracorporeal
lesions (k=0.412) while 93.3% had concordant
PR and concordant Her-2/ neu expression (k=0.842 for
PR and 0.634 for Her-2/ neu)
Conclusion: PR expression was significantly higher
in the primary tumors than the extra-corporeal sites.
Higher ER and lower Her-2/ neu expressions in the
primary tumors were also observed but the differences
were not significant. The tumors heterogeneity suggests
it may be important to study tumor tissues from both
primary and extra-corporeal sites when planning
treatment, especially by hormonal or targeted therapies.
publication.page.subject
Citation
Histology and Histopathology, vol. 28, nº 6. (2013)
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.